16:58:41 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017


ListaOB Match
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2022-10-27 09:20:00
Moss, 27 October 2022
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative
diagnostic solutions for improved clinical decision making, has entered into a
global distribution agreement for its GCAL® Calprotectin Immunoassay with a
major diagnostic company.

"This is the second distribution agreement for GCAL® announced this year, which
confirms the products' value proposition and market potential. The agreement is
a result of our market development efforts, and the fact that we're gaining
commercial traction with several of the world's leading diagnostics companies
supports our long-term growth ambition," says Gentian Diagnostics CEO Hilja

The cooperation is positioned towards the market for detection and assessment of
inflammatory diseases and infections, with launch scheduled for the first half
of 2023, initially in Europe. Depending on regulatory clearance this product
will be available in additional countries and regions at a later stage.

Gentian's commercial strategy is to secure broad roll-out and acceptance of its
products, which requires distribution and awareness through leading global
diagnostics companies.

The Gentian GCAL® Calprotectin Immunoassay is available in the market for
quantitative measurements of calprotectin in plasma and serum samples and based
on published scientific findings it is expected to become a key clinical value

According to the stock exchange release dated 28 September 2022, Gentian
obtained the European In-Vitro Diagnostic Regulation (IVDR) certification for
its first products and the Gentian GCAL® Calprotectin Immunoassay is among these
certified products.

For further information, please contact:
Hilja Ibert, CEO
+47 919 05 242

Njaal Kind, CFO and COO
+47 919 06 525

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protect life. Gentian is based in Moss,
Norway, serving the global and veterinary diagnostics markets through sales and
representative offices in Sweden, USA and China. For more information, please
visit www.gentian.com.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Security Trading Act. This stock exchange
announcement was published by Njaal Kind, CFO & COO at Gentian Diagnostics ASA,
on 27 October 2022 at 09:20 CET.